Department of Health and Human Services$1.1M obligationsEnds Dec 18, 2021
Federal contract award
75N94018F00004
R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541712 |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | HHSN275201300021I |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $1.1M |
| Current contract value | $1.1M |
| Potential contract value / ceiling | $1.1M |
| Start date | Sep 25, 2018 |
| Current end date | Jul 14, 2026 |
| Potential end date | Jul 14, 2026 |
| Latest award activity | Mar 17, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 10 of 10 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 17, 2026 | P00009 | $0 | NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE: NON-SEVERABLE |
| Nov 25, 2025 | P00008 | $8.7K | NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE: NON-SEVERABLE |
| Aug 15, 2025 | P00007 | $35.9K | NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE: NON-SEVERABLE |
| Jul 22, 2025 | P00006 | $0 | NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE: NON-SEVERABLE |
| Sep 27, 2024 | P00005 | $170.7K | TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE. |
| Jan 17, 2024 | P00004 | $210.9K | TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE. |
| Sep 18, 2023 | P00003 | $103.1K | TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE. |
| Apr 11, 2022 | P00002 | $125.9K | TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE. |
| Sep 27, 2021 | P00001 | $176.0K | TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYMANIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG ACTING INJECTABLE. |
| Sep 25, 2018 | 0 | $257.0K | R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT) |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.